Programming the Diabetic Wound: Fabrication-Guided, Phase-Matched Drug-Loaded Polymeric Scaffolds as Carriers and Regenerative Vehicles

Diabetic foot ulcers heal slowly and often incompletely, and the constructs developed to treat them are still described mainly by composition rather than by function. This narrative review treats the drug-loaded polymeric scaffold as a programmable, multiscale platform: programmable in that release timing can be specified and tested rather than merely observed, and multiscale in that the macroscopic construct and an embedded nano-or vesicular carrier impose independent release barriers. Its value depends largely on when agents arrive, not on passive storage. First, reported evidence indicates that the diabetic wound is temporally disordered as well as slow: inflammation begins late and fails to resolve, sustaining excess matrix metalloproteinase-9 (MMP-9), reactive oxygen species (ROS) and a pro-inflammatory macrophage state that has been associated with impaired angiogenesis and remodeling. This suggests a therapeutic schedule — antibacterial, then antioxidant and anti-inflammatory, then angiogenic, then remodeling — against which scaffolds can be judged, although the superiority of sequential over simultaneous delivery remains a design hypothesis rather than a demonstrated result. Second, a single causal chain is traced: the fabrication route sets a scaffold’s release signature, and the position of the drug or of an embedded carrier refines it, separating agents by shifting control from matrix to carrier. Third, constructs are judged against this benchmark: fewer than half of the exemplar constructs examined release their agents in resolved sequence, and phase-matched delivery has been demonstrated mainly in carrier-within-carrier architectures and stimuli-responsive systems. The scaffold’s dual roles as carrier and regenerative template, and the evidence standards required for translation, are also identified.